Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BBSRC is investing £10m in 20 advanced scientific research instruments.

BBSRC is investing £10m in 20 advanced scientific research instruments under the Advanced Life Sciences Research Technology initiative (ALERT 13) to help keep the UK at the forefront of biological sciences research. Shankar Srinivas and Paul Riley from the Department of Physiology, Anatomy and Genetics, together with Ilan Davis (Biochemistry and Micron Oxford Advanced Bioimaging Unit), Jordan Raff (Sir William Dunn School of Pathology) and Roger Patient (Weatherall Institute of Molecular Medicine) have been awarded one of the UK’s first two commercial Fluorescence Light Sheet Microscopes to probe cell and tissue dynamics, worth just under £500k. This instrument will allow groups from Oxford and further afield to examine dynamic process within living cells in exquisite detail, enabling exciting advances in a broad range of areas in cell, developmental and stem cell biology.

Read more

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.